Company profile TARA

Protara Therapeutics Inc
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacem...ent therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york. Show More
Quarter analysis & expected interestLast update: February 09 2024 11:14:55.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Protara Therapeutics expected interest is significantly lower compared to previous quarter (-100.0%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201984
51
-39.3% QoQ
50
-2.0% QoQ
21
-58.0% QoQ
2020 80
-4.8% YoY 281.0% QoQ
107
109.8% YoY 33.8% QoQ
74
48.0% YoY -30.8% QoQ
224
966.7% YoY 202.7% QoQ
2021 101
26.2% YoY -54.9% QoQ
108
0.9% YoY 6.9% QoQ
124
67.6% YoY 14.8% QoQ
159
-29.0% YoY 28.2% QoQ
2022 171
69.3% YoY 7.5% QoQ
114
5.6% YoY -33.3% QoQ
103
-16.9% YoY -9.6% QoQ
73
-54.1% YoY -29.1% QoQ
2023 0
-100.0% YoY -100.0% QoQ
121
6.1% YoY inf% QoQ
194
88.3% YoY 60.3% QoQ
45
-38.4% YoY -76.8% QoQ
2024 0
-38.4% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Protara Therapeutics search interestLast update: February 09 2024 11:14:54.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 11:14:56.

The average 5 years interest of Protara Therapeutics was 7.68 per week.
The last year interest of Protara Therapeutics compared to the last 5 years has changed by -9.9%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 49.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for lymphatic malformations treatment to provide analysis

Correlation between past revenue and lymphatic malformations treatment search interest

There is not enough data for lymphatic malformations treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for lymphatic malformations treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TARA-002 cell therapy to provide analysis

Correlation between past revenue and TARA-002 cell therapy search interest

There is not enough data for TARA-002 cell therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TARA-002 cell therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 11:15:03.

After 39 days of this quarter the interest is at 138.0. Based on that we can calculate that during remaining 52 days it will total up to 322.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019133
247
85.7% QoQ
368
49.0% QoQ
232
-37.0% QoQ
2020 231
73.7% YoY -0.4% QoQ
204
-17.4% YoY -11.7% QoQ
225
-38.9% YoY 10.3% QoQ
180
-22.4% YoY -20.0% QoQ
2021 238
3.0% YoY 32.2% QoQ
143
-29.9% YoY -39.9% QoQ
143
-36.4% YoY 0.0% QoQ
238
32.2% YoY 66.4% QoQ
2022 304
27.7% YoY 27.7% QoQ
271
89.5% YoY -10.9% QoQ
344
140.6% YoY 26.9% QoQ
230
-3.4% YoY -33.1% QoQ
2023 267
-12.2% YoY 16.1% QoQ
350
29.2% YoY 31.1% QoQ
195
-43.3% YoY -44.3% QoQ
362
57.4% YoY 85.6% QoQ
2024 138
-48.3% YoY -61.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and rare disease treatment search interestLast update: February 09 2024 11:15:01.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 11:15:03.

The average 5 years interest of rare disease treatment was 19.32 per week.
The last year interest of rare disease treatment compared to the last 5 years has changed by 22.31%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 6.39%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for intravenous choline chloride to provide analysis

Correlation between past revenue and intravenous choline chloride search interest

There is not enough data for intravenous choline chloride to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for intravenous choline chloride to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for intestinal failure associated liver disease to provide analysis

Correlation between past revenue and intestinal failure associated liver disease search interest

There is not enough data for intestinal failure associated liver disease to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for intestinal failure associated liver disease to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 11:15:10.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
ArTara Therapeutics expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201956
70
25.0% QoQ
89
27.1% QoQ
112
25.8% QoQ
2020 72
28.6% YoY -35.7% QoQ
62
-11.4% YoY -13.9% QoQ
40
-55.1% YoY -35.5% QoQ
134
19.6% YoY 235.0% QoQ
2021 35
-51.4% YoY -73.9% QoQ
19
-69.4% YoY -45.7% QoQ
60
50.0% YoY 215.8% QoQ
135
0.7% YoY 125.0% QoQ
2022 67
91.4% YoY -50.4% QoQ
83
336.8% YoY 23.9% QoQ
71
18.3% YoY -14.5% QoQ
72
-46.7% YoY 1.4% QoQ
2023 71
6.0% YoY -1.4% QoQ
57
-31.3% YoY -19.7% QoQ
207
191.5% YoY 263.2% QoQ
85
18.1% YoY -58.9% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ArTara Therapeutics search interestLast update: February 09 2024 11:15:09.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 11:15:14.

The average 5 years interest of ArTara Therapeutics was 6.12 per week.
The last year interest of ArTara Therapeutics compared to the last 5 years has changed by 22.88%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 6.82%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Protara Therapeutics headquarters to provide analysis

Correlation between past revenue and Protara Therapeutics headquarters search interest

There is not enough data for Protara Therapeutics headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Protara Therapeutics headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 11:15:37.

After 39 days of this quarter the interest is at 50.0. Based on that we can calculate that during remaining 52 days it will total up to 117.0.
Protara Therapeutics stock expected interest is significantly higher compared to same quarter last year (+46.2%) but similar to previous quarter.

YearQ1Q2Q3Q4
201917
106
523.5% QoQ
143
34.9% QoQ
68
-52.4% QoQ
2020 29
70.6% YoY -57.4% QoQ
22
-79.2% YoY -24.1% QoQ
127
-11.2% YoY 477.3% QoQ
0
-100.0% YoY -100.0% QoQ
2021 98
237.9% YoY inf% QoQ
175
695.5% YoY 78.6% QoQ
85
-33.1% YoY -51.4% QoQ
104
inf% YoY 22.4% QoQ
2022 109
11.2% YoY 4.8% QoQ
124
-29.1% YoY 13.8% QoQ
51
-40.0% YoY -58.9% QoQ
51
-51.0% YoY 0.0% QoQ
2023 80
-26.6% YoY 56.9% QoQ
175
41.1% YoY 118.8% QoQ
52
2.0% YoY -70.3% QoQ
112
119.6% YoY 115.4% QoQ
2024 50
-37.5% YoY -55.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Protara Therapeutics stock search interestLast update: February 09 2024 11:15:35.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 11:15:38.

The average 5 years interest of Protara Therapeutics stock was 6.81 per week.
The last year interest of Protara Therapeutics stock compared to the last 5 years has changed by 17.47%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 19.23%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TARA
Earnings date: 2024-03-06 After close
Company name: Protara Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-15T11:00:00Z

GlobeNewswire
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

2026-05-14T18:19:35Z

Analyst Upgrades
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

2026-05-13T12:00:00Z

GlobeNewswire
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

2026-04-29T11:39:27Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

2026-04-27T20:05:00Z

GlobeNewswire
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

2026-03-10T12:00:00Z

GlobeNewswire
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

2026-03-04T12:35:11Z

Analyst Upgrades
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

2026-02-23T22:05:00Z

GlobeNewswire
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

2026-02-19T13:00:00Z

GlobeNewswire
Protara Therapeutics to Participate in Upcoming Investor Conferences

2026-02-10T12:05:27Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

2026-02-02T21:05:25Z

GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-22T13:00:00Z

GlobeNewswire
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

2026-01-12T12:00:00Z

GlobeNewswire
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

2026-01-07T13:10:08Z

Analyst Upgrades
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24

2026-01-07T13:00:00Z

GlobeNewswire
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference